Nektar Therapeutics to Raise $250 Million in Public Offering
Event summary
- Nektar Therapeutics announced a public offering of $250 million in common stock and pre-funded warrants.
- The company has a 30-day option to sell an additional $37.5 million in stock.
- Proceeds will primarily fund research and development, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.
- The offering is being made under a shelf registration statement filed with the SEC on November 12, 2025.
The big picture
Nektar's decision to pursue a significant public offering underscores the substantial capital requirements of late-stage clinical development, particularly in the competitive immunotherapy space. The move suggests a need to bolster the company’s financial runway to support rezpegaldesleukin's advancement, highlighting the inherent risks associated with drug development. The involvement of Jefferies, TD Cowen, and Piper Sandler indicates a desire to tap into established distribution networks for biotech equity.
What we're watching
- Capital Structure
- The dilution effect of this offering on existing shareholders warrants close monitoring, particularly given the company's ongoing clinical trial expenses.
- Clinical Execution
- Success in the Phase 3 trials for rezpegaldesleukin will be critical to justifying the capital raise and maintaining investor confidence.
- Market Sentiment
- The pricing and ultimate size of the offering will reflect broader investor appetite for clinical-stage biotech companies, potentially signaling shifts in market risk tolerance.
Related topics